The Future of Regulatory Compliance in India
India’s pharmaceutical industry, recognized as the "pharmacy of the world," finds itself at a critical point in its evolution, adapting to rapidly changing regulatory landscapes. With an increasing emphasis on quality, safety, and efficacy, the future of regulatory compliance in India presents both transformative opportunities and challenges. Companies of all sizes will need to innovate and implement robust practices to remain competitive amid heightened scrutiny and alignment with global standards.
A key shift in this landscape is the comprehensive integration of guidelines outlined in Schedule M. In the coming years, all pharmaceutical companies, regardless of size, will need to rigorously apply these guidelines. The alignment of Schedule M with WHO’s Technical Report Series (TRS) and ISO standards underscores its growing significance. As of January 2024, only about 2,000 out of approximately 10,500 drug manufacturing units in India meet WHO’s GMP guidelines, indicating that a large proportion of both small and large manufacturers are still working towards compliance. Government initiatives and financial backing are playing a critical role in closing this gap, particularly for smaller manufacturers. The "Pharma MSME Scheme" has provided vital financial support to a lot of small-scale manufacturers, assisting them in upgrading their facilities to meet GMP standards. Similarly, programs like the "Cluster Development Program" have encouraged collaboration among small manufacturers, enabling them to share resources and collectively improve their compliance processes.
The Pharmaceutical Quality System (PQS) is becoming an increasingly central element of compliance. These systems, which focus on risk management, documentation, and continuous improvement, will soon be mandatory for all pharmaceutical operations. Smaller manufacturers are also embracing PQS, with many reporting improvements in documentation practices, which in turn facilitate smoother regulatory audits and faster product approvals. Although precise statistics on the adoption of PQS across the industry are hard to come by, it is clear that companies are prioritizing these systems to anticipate stricter regulations and gain a strategic advantage. This shift is more than just a regulatory requirement; it is a business imperative for reducing operational risks and enhancing the reliability of products.
Manufacturing processes such as process validation, cleaning validation, and hold time studies are gaining increasing importance in this new regulatory framework. Process validation ensures consistency across batches and compliance with quality standards, while cleaning validation is critical in preventing cross-contamination—both key elements of Schedule M and WHO regulations. Hold time studies, which assess storage times at different stages of production, are now essential for ensuring product stability.
Recent government crackdowns on non-compliance have highlighted the importance of adhering to these standards. In February 2024, the Central Drugs Standard Control Organization (CDSCO) took stringent action against non-compliant facilities, with 64 pharmaceutical companies having their licenses canceled and 17 drug testing laboratories ordered to shut down for failing to meet GMP and other procedural requirements. The CDSCO had been conducting risk-based inspections since December 2022, and the results were stark: around 36% of the inspected pharmaceutical manufacturing units were found to be non-compliant, leading to their temporary or permanent shutdowns. Many of these units failed to meet basic documentation, validation processes, or lacked fully operational quality control labs. The CDSCO's efforts have resulted in a significant decrease in international quality complaints, a move welcomed by industry stakeholders who have been working to regain trust after the Gambia cough syrup incident, where toxic Indian-made syrups led to fatalities.
The government’s "Production Linked Incentive (PLI) Scheme for Pharmaceuticals" is playing an important role in helping companies upgrade their compliance practices. With a total budget of ₹15,000 crore over six years, the scheme is enabling significant investments in infrastructure, technology, and workforce training, which are especially beneficial to small-scale manufacturers. Such government-backed incentives are vital for helping manufacturers remain competitive and meet global standards, but it would be useful to explore additional ways in which smaller companies can leverage these resources to their advantage.
The regulatory environment has become more stringent, with the CDSCO increasing its risk-based inspections across India. These inspections have highlighted significant gaps in adherence to Schedule M, particularly in areas like validation protocols and documentation, underscoring the necessity of ensuring compliance. This growing regulatory scrutiny is a wake-up call for the industry, emphasizing that adherence to compliance is no longer an optional luxury but a business necessity. Furthermore, environmental sustainability is beginning to play a larger role in regulatory frameworks. While eco-friendly manufacturing practices have not yet been fully integrated into Schedule M, global shifts towards sustainability mean that future guidelines are likely to include stricter measures for waste management and carbon footprint reduction. Manufacturers who proactively adopt sustainable practices will be better positioned to meet these future requirements and strengthen their reputations among environmentally-conscious stakeholders.
As India’s pharmaceutical industry faces this evolving regulatory landscape, companies must prioritize innovation, compliance, and sustainability. By embracing new technologies, investing in quality systems, and ensuring that all operations adhere to the latest guidelines, businesses can secure their place in a competitive global market. The companies that navigate these changes most effectively will likely enjoy long-term success, benefiting from stronger relationships with regulators, enhanced operational efficiency, and improved market standing. Fayakun Healthcare are at the forefront for helping the industry adjust to these new demands, offering expertise in areas such as tech transfer, PQS implementation, audit readiness, and risk management. As the industry continues to transform, companies should focus not just on meeting compliance requirements but on adopting a forward-thinking, proactive approach to regulatory challenges. By doing so, they can position themselves for success in the rapidly evolving global pharmaceutical market.
For more information visit our website : fayakunhealthcare.com
Reference
Indian regulator says 36% of inspected drug-making units had to be shut
India Pharmaceutical Adopting Automation Technologies
Evolving Regulatory Compliances Vs. Digital Adoption initiatives by Indian Pharma industry
Regulatory, policy reforms crucial for future of India's pharma R&D: Report
Navigating India's Recent Regulatory Changes for Pharmaceutical Companies
Comments
Post a Comment